Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

UroGen Pharma (URGN) Assets Average: 2017-2025

Historic Assets Average for UroGen Pharma (URGN) over the last 8 years, with Sep 2025 value amounting to $196.9 million.

  • UroGen Pharma's Assets Average fell 32.55% to $196.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.9 million, marking a year-over-year decrease of 32.55%. This contributed to the annual value of $232.0 million for FY2024, which is 47.81% up from last year.
  • Per UroGen Pharma's latest filing, its Assets Average stood at $196.9 million for Q3 2025, which was down 13.71% from $228.2 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Assets Average ranged from a high of $293.8 million in Q4 2024 and a low of $104.2 million during Q2 2023.
  • Moreover, its 3-year median value for Assets Average was $196.9 million (2025), whereas its average is $206.1 million.
  • Per our database at Business Quant, UroGen Pharma's Assets Average plummeted by 40.59% in 2021 and then surged by 131.58% in 2024.
  • UroGen Pharma's Assets Average (Quarterly) stood at $127.2 million in 2021, then climbed by 3.83% to $132.0 million in 2022, then soared by 40.84% to $186.0 million in 2023, then spiked by 58.00% to $293.8 million in 2024, then crashed by 32.55% to $196.9 million in 2025.
  • Its last three reported values are $196.9 million in Q3 2025, $228.2 million for Q2 2025, and $266.7 million during Q1 2025.